Related Experiment Videos
Platelet monoamine oxidase in schizophrenia and manic-depressive illness
Abstract:
Monoamine oxidase (MAO) is an important enzyme in the catabolism of brain biogenic amines. Platelet MAO has been reported to be moderately reduced in manic-depressive patients and markedly reduced in schizophrenic patients. This enzyme's activity has been shown to be under a large degree of genetic control and has been proposed as a 'genetic marker' in schizophrenia. A transcultural replication of the finding of low platelet MAO in schizophrenia and manic-depressive illness was carried out at the Jerusalem Mental Health Centre. Manic-depressive patients were found to have higher platelet MAO activity than schizophrenic patients, as reported previously, but control individuals were as low as the schizophrenic patients. It is unlikely that platelet MAO activity is a transculturally-valid marker for schizophrenia.
Insights
Platelet monoamine oxidase (MAO) activity was studied in Jerusalem. Low MAO activity was observed in both schizophrenic patients and healthy controls, suggesting it is not a reliable genetic marker for schizophrenia across cultures.
Area of Science:
- Neuroscience
- Psychiatry
- Genetics
Background:
- Monoamine oxidase (MAO) is crucial for breaking down biogenic amines in the brain.
- Previous studies suggested reduced platelet MAO activity in schizophrenia and manic-depressive illness.
- Platelet MAO has been considered a potential genetic marker for schizophrenia due to its heritability.
Purpose of the Study:
- To conduct a transcultural replication of findings regarding platelet MAO activity in schizophrenia and manic-depressive illness.
- To investigate the validity of platelet MAO as a transculturally-reliable genetic marker for schizophrenia.
Main Methods:
- Platelet monoamine oxidase (MAO) activity was measured in patients diagnosed with schizophrenia and manic-depressive illness.
- Activity levels were compared between patient groups and healthy control individuals.
- The study was conducted at the Jerusalem Mental Health Centre to assess transcultural validity.
Main Results:
- Manic-depressive patients exhibited higher platelet MAO activity compared to schizophrenic patients.
- Healthy control individuals showed MAO activity levels as low as those observed in schizophrenic patients.
- These findings contrast with previous reports suggesting a distinct reduction in MAO for both patient groups.
Conclusions:
- The observed pattern of platelet MAO activity in Jerusalem does not support its use as a transculturally-valid marker for schizophrenia.
- The genetic control of MAO activity may manifest differently across diverse populations.
- Further research is needed to understand the complex role of MAO in psychiatric disorders and its potential as a biomarker.